Association Between Argatroban and Outcomes of Branch Atheromatous Disease: A Propensity‐Matched Analysis From MRI ‐Based Study
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70467 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Shengde Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical …. Hauptthemen laut MEDLINE: Sulfonamides, Arginine, Pipecolic Acids, Plaque, Atherosclerotic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Medical and Health Science and Technology Innovation Project of Chinese Academy of Medical Sciences, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Background and Purpose Argatroban is widely used for patients with acute branch atheromatous disease (BAD)‐related stroke, but its efficacy remains unclear. This study aims to evaluate its clinical outcomes in this patient population.
Methods
A prospective, MRI‐based cohort (BAD‐study) was conducted across 20 hospitals in China from June 2021 to June 2023, enrolling patients aged 18–80 years with BAD‐related stroke within 72 h of onset. Patients were divided into two groups: Argatroban and non‐argatroban. The primary outcome was an excellent outcome, defined as a modified Rankin Scale (mRS) score of 0–1 at 90 days. Secondary outcomes included good outcome (mRS 0–2), mRS score, Barthel Index score at 90 days, and NIHSS score at 7 days. Logistic regression analyses were performed to assess the association between argatroban and outcomes after propensity score matching (PSM).
Results
A total of 467 patients were included, with a median age of 60 years and a median NIHSS score of 4 at admission. Eighty‐six patients (18.4%) were in the argatroban group, and 381 patients (81.6%) were in the non‐argatroban group. After PSM, excellent outcomes occurred in 60.0% of the argatroban group and 64.2% of the non‐argatroban group (odds ratio [OR] = 0.84, 95% CI: 0.47–1.49, p = 0.542). Argatroban was not significantly associated with secondary outcomes and remained ineffective in sensitivity analyses.
Conclusion
Argatroban was not associated with excellent outcome at 90 days in patients with acute BAD‐related stroke. Our study suggests that the risks and benefits of argatroban need reevaluation in patients with BAD‐related stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- Department of Neurology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, China.
- Department of Neurology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
- Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Department of Neurology, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei, China.
ORCID-Profile: Shengde Li, Guofang Chen, Jun Ni
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Medical and Health Science and Technology Innovation Project of Chinese Academy of Medical Sciences
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Li, S., Hu, H., Zhou, Y., Zhang, P., Chen, G., Bai, H., Liu, B., Zhou, L., Zhu, Y., Peng, B., Ni, J., & BAD‐study investigators (2025). Association Between Argatroban and Outcomes of Branch Atheromatous Disease: A Propensity‐Matched Analysis From MRI ‐Based Study. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70467
Vancouver
Li S, Hu H, Zhou Y, Zhang P, Chen G, Bai H, et al. Association Between Argatroban and Outcomes of Branch Atheromatous Disease: A Propensity‐Matched Analysis From MRI ‐Based Study. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70467
BibTeX
@article{Li2025,
author = {Li, Shengde and Hu, Haizhou and Zhou, Yaping and Zhang, Ping and Chen, Guofang and Bai, Hongying and Liu, Bin and Zhou, Lixin and Zhu, Yicheng and Peng, Bin and Ni, Jun and BAD‐study investigators, BAD‐study investigators},
title = {Association Between Argatroban and Outcomes of Branch Atheromatous Disease: A Propensity‐Matched Analysis From MRI ‐Based Study},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70467}
}
EUVIMED